Showing 2 posts of 2 posts found.

NICE recommends Pfizer’s Vizimpro, rejects AstraZeneca’s Tagrisso, in non-small cell lung cancer

July 5, 2019
Medical Communications, Sales and Marketing Cancer, NHS, NICE, Pfizer, UK, Vizimpro, lung cancer, pharma

NICE has announced its decision to recommend Pfizer’s Vizimpro (Dacomitinib) in the treatment of non-small-cell lung cancer (NSCLC) – a …

European approval for Pfizer’s Vizimpro in first-line non-small cell lung cancer

April 4, 2019
Sales and Marketing Cancer, Europe, Pfizer, Vizimpro, lung cancer, non small cell lung cancer, non-small cell lung cancer, pharma

The European Commission has awarded marketing approval to Pfizer’s tyrosine kinase inhibitor (TKI) Vizimpro (dacomitinib), it has emerged, as a …

Latest content